Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 3,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Surgical Management Clear all

Conditions: Acute Kidney Injury
Interventions: Nitric Oxide, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Cancer
Interventions: CA 125 and CT scan; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2018
U.S. locations: 5
States / cities: Baltimore, Maryland • Basking Ridge, New Jersey • Commack, New York + 2 more

Conditions: Noncardiac Surgery
Interventions: Fluid; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 21 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Low Grade Glioma, Malignant Brain Glioma, Malignant Brain Neoplasm, Meningioma
Interventions: Biospecimen Collection, Computed Tomography, Dexamethasone, Magnetic Resonance Imaging, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Spinal Ischemia, Stroke, Neuroprotection
Interventions: Darbepoetin alfa, Standard care; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 100 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma
Interventions: PET-CT Scan; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sacroiliac Joint Pain
Interventions: Bone Allograft, Conventional Medical Management (CMM); Procedure · Other
Lead sponsor: PainTEQ, LLC; Industry
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Shenandoah, Texas

Conditions: Hypogonadism, Kallmann Syndrome
Interventions: Testicular biopsy, gonadotropin releasing hormone (GnRH), follicle stimulating hormone (FSH); Procedure · Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 493
States / cities: Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more

Conditions: Cerebrospinal Fluid Leakage, Subdural
Interventions: Spinal Sealant, Standard of Care; Device · Other
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bedford, Massachusetts

Conditions: Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity
Interventions: bortezomib, dexamethasone, melphalan, thalidomide, cytogenetic analysis, fluorescence in situ hybridization, laboratory biomarker analysis, questionnaire administration, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Drug · Genetic · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Up to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Duarte, California

Conditions: Cardiovascular Risk Factors
Interventions: Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE); Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 100 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v8, Stage II Renal Cell Cancer AJCC v8
Interventions: Magnetic Resonance Imaging, Questionnaire Administration, Stereotactic Body Radiation Therapy; Procedure · Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: NDURE; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Degenerative Disc Disease, DDD, Degenerative Disc Disease Lumbar, Degenerative Disc Disease, Lumbar, Lumbar Disc Herniation, Disc Herniation, Lumbar, Bone Marrow Aspirate Concentrate, Intervertebral Disc Displacement, Low Back Pain, Chronic Low Back Pain (CLBP), CLBP - Chronic Low Back Pain
Interventions: Bone Marrow Aspirate Concentrate (BMAC); Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Manhattan, New York

Conditions: Breast Cancer
Interventions: Hypofractionated radiotherapy, Pembrolizumab infusion, Blood and tissue sampling; Radiation · Drug · Procedure
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Otitis Media
Interventions: Tympanocentesis, Nose/throat swab, Observational; Procedure · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 6 Months to 30 Months
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 7
States / cities: Penfield, New York • Rochester, New York

Conditions: Diabetic Foot Ulcer
Interventions: Dermagraft(R), Conventional care; Device · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1997
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 122
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more

Conditions: Human Papillomavirus Infection, Stage I Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions: Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery; Biological · Other · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cataract
Interventions: Clobetasol Propionate, Vehicle; Drug
Lead sponsor: Salvat; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 18
States / cities: Sun City, Arizona • Hemet, California • Inglewood, California + 15 more

Conditions: Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
Interventions: DermaBind TL; Biological
Lead sponsor: HealthTech Wound Care; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 10
States / cities: DeLand, Florida • Palm Beach Gardens, Florida • Sweetwater, Florida + 7 more

Conditions: Sanfilippo Syndrome
Interventions: Recombinant human heparan N-sulfatase [rhHNS]; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Months to 48 Months
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Torrance, California • Minneapolis, Minnesota • Chapel Hill, North Carolina

Conditions: Invasive Breast Cancer
Interventions: PVSRIPO; Biological
Lead sponsor: Istari Oncology, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.

A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer

ZYNEX Cardiac Monitor in Patients Having Noncardiac Surgery

Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial

The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial

PET-CT in the Management of Patients With Stage III or IV Metastatic Melanoma

LINQ® Procedure vs. Conventional Medical Management for Sacroiliac Dysfunction

Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Study to Evaluate Safety & Effectiveness of Spinal Sealant

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Echocardiography Management for Patients Requiring Care for Non-Cardiac Surgery

MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial

Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC

Biologic Injection For Adults With Lumbar Disc Herniation

BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy

Effect of Prevnar 13 on Ear Infections in Children

Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL

Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease

Examining Bioactivity of PVSRIPO in Invasive Breast Cancer